Vaccines

As the company announces that its single-dose Janssen COVID-19 Vaccine has been granted Emergency Use Authorization by the U.S. Food and Drug Administration, here are some key facts about how it works (hint: it involves an inactivated common cold virus), how it has been studied, how it would be transported—and more.

The company is proud to have placed in the top 20 on the prestigious list for its commitment to innovation, dedication to social responsibility and the quality of its products, among other noteworthy attributes—all in the face of a global pandemic.

The Access to Medicine Index, a ranking of pharmaceutical companies’ work to distribute medications to low- and middle-income countries, just named Johnson & Johnson #3 on its biennial list, underscoring the company’s deep history of ensuring people in underserved communities receive the treatments they need.

A potential COVID-19 vaccine. Passionate efforts toward achieving racial and social justice. Smarter, more sustainable product packaging. These are just a few of the resolutions company change makers are aiming to bring to light this year—and they’re already hard at work on them.

Tracking the spread of the virus in real time. Analyzing data to learn more about who’s most vulnerable. These are just a couple of ways the company’s data science team is helping inform how to respond to the pandemic.

Njira Lugogo, M.D., is a pulmonologist at the University of Michigan who is leading a clinical study of an investigational COVID-19 vaccine candidate. She helps answer common questions people may have about the process, from what people over 60 need to know to how participants are being kept safe during the pandemic.

In signing the communiqué, Johnson & Johnson and 15 other life science companies are committing to prioritize the safety, science and accessibility of the potential vaccines, therapeutic medicines or diagnostic tools they are developing to help fight the pandemic.

Johnson & Johnson just announced the launch of a Phase 3 clinical trial for its COVID-19 vaccine candidate. But what does this step in the process really mean? We asked two experts whose job it is to test vaccines to help demystify the clinical trial process—step by step.

In signing the pledge, we are joining eight other biopharmaceutical companies working on vaccine research and development in making the safety and well-being of vaccinated individuals our top priority.

With its global Phase 3 clinical trial now fully enrolled with approximately 45,000 adult participants, we share the most up-to-date information about the single-dose investigational vaccine candidate.